Clinically meaningful biomarkers for psychosis: A systematic and quantitative review

Neuroscience and Biobehavioral Reviews

Volumn 45, Issue , 2014, Pages 134-141

  Prata, Diana ^a   Mechelli, Andrea ^a   Kapur, Shitij ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Antipsychotic; Biomarker; Diagnosis; Marker; Pharmacogenetics; Prediction; Prognosis; Psychosis; Schizophrenia; Treatment response

Indexed keywords

CLOZAPINE; BIOLOGICAL MARKER;

AGRANULOCYTOSIS; DEMOGRAPHY; HUMAN; METABOLIC PARAMETERS; NEUROIMAGING; PHARMACOGENETICS; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; TREATMENT RESPONSE; DISEASE ASSOCIATION; DISEASE COURSE; EXTERNAL VALIDITY; LONGITUDINAL STUDY; MEDICAL RESEARCH; OUTCOME ASSESSMENT; PREDICTION; PUBLICATION; QUANTITATIVE ANALYSIS; RELIABILITY; REPRODUCIBILITY; SYNDROME DELINEATION; VALIDATION PROCESS; GENETICS; METABOLISM; NOMENCLATURE; PSYCHOTIC DISORDERS; PUBLISHING;

BIOMARKERS; HUMANS; PSYCHOTIC DISORDERS; PUBLISHING; TERMINOLOGY AS TOPIC;

EID: 84902295643     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2014.05.010     Document Type: Review

References (32)

1. Andre F., McShane L.M., Michiels S., Ransohoff D.F., Altman D.G., Reis-Filho J.S., et al. Biomarker studies: a call for a comprehensive biomarker study registry. Nat. Rev. Clin. Oncol. 2011, 8:171-176.
2. Aronson J.K. Biomarkers and surrogate endpoints. Br. J. Clin. Pharmacol. 2005, 59:491-494.
3. Arteaga C.L., Sliwkowski M.X., Osborne C.K., Perez E.A., Puglisi F., Gianni L. Treatment of HER2-positive breast cancer: current status and future perspectives. Nat. Rev. Clin. Oncol. 2012, 9:16-32.
4. Athanasiou M.C., Dettling M., Cascorbi I., Mosyagin I., Salisbury B.A., Pierz K.A., et al. Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis. J. Clin. Psychiatry 2011, 72:458-463.
5. Bedard P.L., Krzyzanowska M.K., Pintilie M., Tannock I.F. Statistical power of negative randomized controlled trials presented at American Society for Clinical Oncology annual meetings. J. Clin. Oncol. 2007, 25:3482-3487.
6. Bossuyt P.M., Reitsma J.B., Bruns D.E., Gatsonis C.A., Glasziou P.P., Irwig L.M., et al. Towards complete and accurate reporting of studies of diagnostic accuracy: the STARD initiative. Clin. Biochem. 2003, 36:1-7.
7. Cohen J. Statistical Power Analysis for the Behavioral Sciences 1988, L. Erlbaum Associates, Hillsdale, NJ. second ed.
8. Committee NRCU Toward precision medicine: building a knowledge network for biomedical research and a new taxonomy of disease. Toward Precision Medicine: Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease 2011, Washington (DC). (US) NAP (Ed.).
9. Dettling M., Cascorbi I., Opgen-Rhein C., Schaub R. Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens. Pharmacogenomics J. 2007, 7:325-332.
10. Doraiswamy P.M., Sperling R.A., Coleman R.E., Johnson K.A., Reiman E.M., Davis M.D., et al. Amyloid-beta assessed by florbetapir F 18 PET and 18-month cognitive decline: a multicenter study. Neurology 2012, 79:1636-1644.
11. Goodman A.B., Rahav M., Popper M., Ginath Y., Pearl E. The reliability of psychiatric diagnosis in Israel's Psychiatric Case Register. Acta Psychiatr. Scand. 1984, 69:391-397.
12. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
13. Group B.D.W. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin. Pharmacol. Therap. 2001, 69:89-95.
14. Grove W.M., Andreasen N.C., McDonald-Scott P., Keller M.B., Shapiro R.W. Reliability studies of psychiatric diagnosis. Theory and practice. Arch. Gen. Psychiatry 1981, 38:408-413.
15. Ioannidis J.P. Excess significance bias in the literature on brain volume abnormalities. Arch. Gen. Psychiatry 2011, 68:773-780.
16. Jennings R.G., Van Horn J.D. Publication bias in neuroimaging research: implications for meta-analyses. Neuroinformatics 2012, 10:67-80.
17. Kapur S., Phillips A.G., Insel T.R. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it?. Mol. Psychiatry 2012, 1174-1179.
18. Kitamura T., Shima S., Sakio E., Kato M. Psychiatric diagnosis in Japan. 2. Reliability of conventional diagnosis and discrepancies with Research Diagnostic Criteria diagnosis. Psychopathology 1989, 22:250-259.
19. Lassere M.N. The Biomarker-Surrogacy Evaluation Schema: a review of the biomarker-surrogate literature and a proposal for a criterion-based, quantitative, multidimensional hierarchical levels of evidence schema for evaluating the status of biomarkers as surrogate endpoints. Stat. Methods Med. Res. 2008, 17:303-340.
20. Lawrie S.M., Olabi B., Hall J., McIntosh A.M. Do we have any solid evidence of clinical utility about the pathophysiology of schizophrenia?. World Psychiatry 2011, 10:19-31.
21. Leucht S., Hierl S., Kissling W., Dold M., Davis J.M. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br. J. Psychiatry 2012, 200:97-106.
22. Lieberman J.A. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia: efficacy, safety and cost outcomes of CATIE and other trials. J. Clin. Psychiatry 2007, 68:e04.
23. McIntosh A.M., Gow A., Luciano M., Davies G., Liewald D.C., Harris S.E., et al. Polygenic risk for schizophrenia is associated with cognitive change between childhood and old age. Biol. Psychiatry 2013, 73:938-943.
24. Novack G.D. The CONSORT statement for publication of controlled clinical trials. Ocul. Surf. 2004, 2:45-46.
25. Oldenhuis C.N., Oosting S.F., Gietema J.A., de Vries E.G. Prognostic versus predictive value of biomarkers in oncology. Eur. J. Cancer 2008, 44:946-953.
26. Perlis R.H. Translating biomarkers to clinical practice. Mol. Psychiatry 2011, 16:1076-1087.
27. Perlis R.H., Patrick A., Smoller J.W., Wang P.S. When is pharmacogenetic testing for antidepressant response ready for the clinic? A cost-effectiveness analysis based on data from the STAR*D study. Neuropsychopharmacology 2009, 34:2227-2236.
28. Reveiz L., Krleza-Jeric K., Chan A.-W., De Aguiar S. Do trialists endorse clinical trial registration? Survey of a Pubmed sample. Trials 2007, 8:30.
29. Simmons J.M., Quinn K.J. The NIMH Research Domain Criteria (RDoC) Project: implications for genetics research. Mamm. Genome 2013, 23-31.
30. Simon G.E., Perlis R.H. Personalized medicine for depression: can we match patients with treatments?. Am. J. Psychiatry 2010, 167:1445-1455.
31. Trusheim M.R., Berndt E.R., Douglas F.L. Stratified medicine: strategic and economic implications of combining drugs and clinical biomarkers. Nat. Rev. Drug Discov. 2007, 6:287-293.
32. Uher R., Tansey K.E., Malki K., Perlis R.H. Biomarkers predicting treatment outcome in depression: what is clinically significant?. Pharmacogenomics 2012, 13:233-240.